Diseases /
Myeloproliferative Neoplasm
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008) [1]
Myeloproliferative neoplasms most frequently harbor alterations in JAK2, TET2, ASXL1, CALR, and DNMT3A [2].
JAK2 Mutation, JAK2 V617F, JAK2 Exon 14 Mutation, CALR Mutation, and ASXL1fs are the most common alterations in myeloproliferative neoplasm [2].
Clinical Trials
Significant Genes in Myeloproliferative Neoplasm
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.